使用 ADA 生物仿制药治疗后出现斑秃:病例报告。

IF 1.2 Q4 RHEUMATOLOGY
Aliki I Venetsanopoulou, Konstantina Mavridou, Eleftherios Pelechas, Paraskevi V Voulgari, Alexandros A Drosos
{"title":"使用 ADA 生物仿制药治疗后出现斑秃:病例报告。","authors":"Aliki I Venetsanopoulou, Konstantina Mavridou, Eleftherios Pelechas, Paraskevi V Voulgari, Alexandros A Drosos","doi":"10.2174/0115733971266803231117072453","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Tumor necrosis factor alpha (TNFα) is a pivotal cytokine involved in the pathogenesis of certain inflammatory diseases, such as rheumatoid arthritis (RA), spondyloarthropathies, and inflammatory bowel diseases. In the last two decades, TNFα inhibitors (TNFi) have revolutionized the treatment and outcome of the above disorders. However, the use of TNFi has been associated with the development of many autoimmune phenomena and paradoxical skin manifestations that may present as the same type of clinical indications for which the TNFi effectively used. Thus, they may display as arthritis, uveitis, colitis, psoriasis, and several other cutaneous clinical manifestations, among them the development of morphea, a localized scleroderma skin lesion.</p><p><strong>Case presentation: </strong>We describe a 58-year-old woman with seronegative RA, refractory to methotrexate, who was treated with ABP-501 (Hefiya), an adalimumab (ADA) biosimilar and developed an oval-shaped, deep skin lesion of approximately 3.5cm in size, affecting the left part of her back compatible with morphea 3 months after the initiation of therapy. ADA biosimilar was discontinued and two months later, she had substantial skin improvement.</p><p><strong>Conclusion: </strong>This is the first report of morphea manifestation during TNFi biosimilar since the patient had no other trigger factors for morphea development like trauma and infections. Physicians dealing with patients treated with TNFi biosimilars should be aware of paradoxical skin reactions, among them morphea; thus, close monitoring, a minute and careful clinical examination, and a follow- up check are required.</p>","PeriodicalId":11188,"journal":{"name":"Current rheumatology reviews","volume":" ","pages":"451-454"},"PeriodicalIF":1.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development of Morphea Following Treatment with an ADA Biosimilar: A Case Report.\",\"authors\":\"Aliki I Venetsanopoulou, Konstantina Mavridou, Eleftherios Pelechas, Paraskevi V Voulgari, Alexandros A Drosos\",\"doi\":\"10.2174/0115733971266803231117072453\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Tumor necrosis factor alpha (TNFα) is a pivotal cytokine involved in the pathogenesis of certain inflammatory diseases, such as rheumatoid arthritis (RA), spondyloarthropathies, and inflammatory bowel diseases. In the last two decades, TNFα inhibitors (TNFi) have revolutionized the treatment and outcome of the above disorders. However, the use of TNFi has been associated with the development of many autoimmune phenomena and paradoxical skin manifestations that may present as the same type of clinical indications for which the TNFi effectively used. Thus, they may display as arthritis, uveitis, colitis, psoriasis, and several other cutaneous clinical manifestations, among them the development of morphea, a localized scleroderma skin lesion.</p><p><strong>Case presentation: </strong>We describe a 58-year-old woman with seronegative RA, refractory to methotrexate, who was treated with ABP-501 (Hefiya), an adalimumab (ADA) biosimilar and developed an oval-shaped, deep skin lesion of approximately 3.5cm in size, affecting the left part of her back compatible with morphea 3 months after the initiation of therapy. ADA biosimilar was discontinued and two months later, she had substantial skin improvement.</p><p><strong>Conclusion: </strong>This is the first report of morphea manifestation during TNFi biosimilar since the patient had no other trigger factors for morphea development like trauma and infections. Physicians dealing with patients treated with TNFi biosimilars should be aware of paradoxical skin reactions, among them morphea; thus, close monitoring, a minute and careful clinical examination, and a follow- up check are required.</p>\",\"PeriodicalId\":11188,\"journal\":{\"name\":\"Current rheumatology reviews\",\"volume\":\" \",\"pages\":\"451-454\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current rheumatology reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115733971266803231117072453\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current rheumatology reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115733971266803231117072453","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:肿瘤坏死因子α(TNFα)是一种关键的细胞因子,参与了某些炎症性疾病的发病机制,如类风湿性关节炎(RA)、脊柱关节病和炎症性肠病。在过去二十年中,TNFα抑制剂(TNFi)彻底改变了上述疾病的治疗和疗效。然而,TNFi的使用也与许多自身免疫现象和矛盾性皮肤表现的出现有关,这些现象和表现可能与TNFi的有效临床适应症类型相同。因此,它们可能表现为关节炎、葡萄膜炎、结肠炎、银屑病和其他一些皮肤临床表现,其中包括发生局部硬皮病皮损--斑秃:我们描述了一名患有血清阴性 RA 且对甲氨蝶呤难治的 58 岁女性患者,她接受了阿达木单抗(ADA)生物类似物 ABP-501 (海飞亚) 的治疗,在开始治疗 3 个月后,她的背部左侧出现了一个约 3.5 厘米大小的椭圆形深层皮损,与莫皮瘤相吻合。停用 ADA 生物类似物两个月后,她的皮肤状况得到了很大改善:这是首例在使用 TNFi 生物类似物期间出现斑秃的报告,因为患者没有其他诱发斑秃的因素,如外伤和感染。医生在接诊使用 TNFi 生物仿制药治疗的患者时,应警惕矛盾性皮肤反应,其中包括斑秃;因此,需要进行密切监测、细致入微的临床检查和随访检查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Development of Morphea Following Treatment with an ADA Biosimilar: A Case Report.

Background: Tumor necrosis factor alpha (TNFα) is a pivotal cytokine involved in the pathogenesis of certain inflammatory diseases, such as rheumatoid arthritis (RA), spondyloarthropathies, and inflammatory bowel diseases. In the last two decades, TNFα inhibitors (TNFi) have revolutionized the treatment and outcome of the above disorders. However, the use of TNFi has been associated with the development of many autoimmune phenomena and paradoxical skin manifestations that may present as the same type of clinical indications for which the TNFi effectively used. Thus, they may display as arthritis, uveitis, colitis, psoriasis, and several other cutaneous clinical manifestations, among them the development of morphea, a localized scleroderma skin lesion.

Case presentation: We describe a 58-year-old woman with seronegative RA, refractory to methotrexate, who was treated with ABP-501 (Hefiya), an adalimumab (ADA) biosimilar and developed an oval-shaped, deep skin lesion of approximately 3.5cm in size, affecting the left part of her back compatible with morphea 3 months after the initiation of therapy. ADA biosimilar was discontinued and two months later, she had substantial skin improvement.

Conclusion: This is the first report of morphea manifestation during TNFi biosimilar since the patient had no other trigger factors for morphea development like trauma and infections. Physicians dealing with patients treated with TNFi biosimilars should be aware of paradoxical skin reactions, among them morphea; thus, close monitoring, a minute and careful clinical examination, and a follow- up check are required.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.30
自引率
0.00%
发文量
82
期刊介绍: Current Rheumatology Reviews publishes frontier reviews on all the latest advances on rheumatology and its related areas e.g. pharmacology, pathogenesis, epidemiology, clinical care, and therapy. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in rheumatology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信